Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2015 Nov 14;4(1):22–26. doi: 10.1016/j.jaip.2015.07.024

Figure 1.

Figure 1

Seasonal variation in exacerbations among children 6 to 20 years of age receiving guidelines based therapy with or without omalizumab: Inner-City Anti-IgE Therapy for Asthma (ICATA)

From: Busse WW et al Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005–15.